Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes (2016 - 2020)

Enanta Pharmaceuticals (ENTA) has disclosed Deferred Taxes for 7 consecutive years, with $15.0 million as the latest value for Q3 2020.

  • For the quarter ending Q3 2020, Deferred Taxes rose 1363.63% year-over-year to $15.0 million, compared with a TTM value of $10.6 million through Sep 2020, up 438.05%, and an annual FY2021 reading of $345000.0, down 96.75% over the prior year.
  • Deferred Taxes was $15.0 million for Q3 2020 at Enanta Pharmaceuticals, up from -$3.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $15.0 million in Q3 2020 and bottomed at -$3.8 million in Q2 2017.
  • Average Deferred Taxes over 5 years is $263052.6, with a median of -$918000.0 recorded in 2018.
  • The sharpest move saw Deferred Taxes crashed 5816.67% in 2016, then skyrocketed 1363.63% in 2020.
  • Year by year, Deferred Taxes stood at -$1.9 million in 2016, then skyrocketed by 239.37% to $2.7 million in 2017, then crashed by 134.49% to -$918000.0 in 2018, then skyrocketed by 171.57% to $657000.0 in 2019, then surged by 2179.15% to $15.0 million in 2020.
  • Business Quant data shows Deferred Taxes for ENTA at $15.0 million in Q3 2020, -$3.1 million in Q2 2020, and -$1.9 million in Q1 2020.